A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE011 (ITA) · Dr. Jansen
consented 2022-04-02
AEs
4
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-10-06 (study day 171); relationship: not assessed
moderate
assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-10-30 (study day 195); relationship: Y
mild
assessed
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-12-30 (study day 256); relationship: not assessed
moderate
assessed
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-01-09 (study day 266); relationship: not assessed
Data queries
No data queries.